-
Considering a proposal for CERF medical prize
Hello all,
I would like to make a proposal to the CERF medical prize 2020.
What I search (and the reason why I post this) is that I need to be backed by a CRO to be credible. CRO are research organizations that could conduct tests on animal models. ALS TDI is an example of CRO that is specialized in ALS.
The key goal of the CERF Medical Prize initiative is to find a successful approach to improve usable muscle strength in MND/ALS patients. Smaller laboratories and individual entrants may apply for support from CERF to develop their projects.
For a few years several academic laboratories in Japan, Canada and USA [1-3] have demonstrated that removing mis-localized TDP-43 aggregates from motor neurons’ cytosol is helpful in ALS animal models.
To my knowledge, no efforts have been made in biotechs to further study those results, so I think it is helpful for ALS patients to raise attention to what those academic laboratories did. One could think that this kind of therapy would nicely complement Nurown or Arimoclomol therapies. One therapy would clean cells, while the other would restore its health.
My proposal to the CERF prize would not use a viral vector to carry a peptide inside cells, as did the academic labs. While this could be done easily, viral vectors have a bad reputation, for example, only a few percent of cells are converted. Their administration mode requires intrathecal injection, something that needs rare medical resources. And there is no way to reverse the effects of the therapy once it is administrated.
Therefore my proposal will use Cell-Penetrating Peptides (CPP). CPPs are not the most efficient mechanism either, but it could be used as much as needed and if there are side effects, it is simple to stop administration. CPPs costs are also much lower than genetic therapy costs.
CPPs could reach the brain via nasal administration, where upper motor neurons have their bodies. They could reach lower motor neurons bodies via Retrograde transport.They are designed in order to bind to the TDP-43 specific domain on one end and bind to an importin protein [4] at the other end.
CPPs could be designed with online tools and tailored to target the cytosol, while not being toxic to the body. There are many free academic prediction servers [5] that could help.
There are many questions to solve: Efficiency, specificity, the toxicity of the proposed therapy.
So if you know someone working in a CRO and if you could advocate for them to join this proposal, a great step toward a way to clean motor neuron cells would be accomplished.
Many thanks for your attention.
Best regards,
Jean-Pierre Le Rouzic
Retired R&D engineer
https://padiracinnovation.org/News/
[1] The Inhibition of TDP-43 Mitochondrial Localization Blocks Its Neuronal Toxicity
Article in Nature medicine · June 2016
DOI: 10.1038/nm.4130
[2] TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic
mouse model for Alzheimer’s disease
Ju Gao, Luwen Wang, Chao Gao, Hiroyuki Arakawa, George Perry, Xinglong Wang
DOI: https://doi.org/10.1016/j.bbadis.2019.165580
[3] Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-
specific intrabody with dual proteolytic signals
Yoshitaka Tamaki , Akemi Shodai , Toshifumi Morimura , Ryota Hikiami , Sumio
Minamiyama , Takashi Ayaki , Ikuo Tooyama , Yoshiaki Furukawa , Ryosuke Takahashi & Makoto
Urushitani
[4] http://pdb101.rcsb.org/motm/85
[5] An example: http://tox.charite.de/protox_II/
Log in to reply.